sucroferric oxyhydroxide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	5121	8047-67-4

Description:

Molecule

Description

Synonyms:

ferric oxyhydroxide
sucroferric oxyhydroxide
velphoro
ferric oxide saccharated
saccharated iron oxide

an oral phosphate binder for treatment of hyperphosphatemia

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

Dose	Unit	Route
0.11	g	O
1.50	g	O

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Nov. 27, 2013	FDA	VIFOR FRESENIUS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Death	418.07	52.26	159	655	374222	63113986
Shunt stenosis	123.75	52.26	18	796	522	63487686
Shunt occlusion	82.40	52.26	13	801	652	63487556
Product taste abnormal	73.92	52.26	14	800	2053	63486155
Diarrhoea	71.42	52.26	64	750	715302	62772906

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Death	618.40	37.90	310	1276	397739	34557606
Shunt stenosis	172.52	37.90	30	1556	752	34954593
Haemoglobin increased	133.77	37.90	31	1555	3378	34951967
Faeces discoloured	116.28	37.90	38	1548	14840	34940505
Shunt occlusion	86.24	37.90	17	1569	853	34954492
Diarrhoea	82.58	37.90	94	1492	389818	34565527
Product taste abnormal	69.73	37.90	15	1571	1159	34954186
Transferrin saturation increased	44.00	37.90	7	1579	99	34955246
Haematocrit increased	41.30	37.90	11	1575	2102	34953243
Serum ferritin increased	41.17	37.90	14	1572	6132	34949213
Tooth discolouration	40.21	37.90	8	1578	420	34954925

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Shunt stenosis	312.22	33.19	48	1492	1343	79741505
Shunt occlusion	178.53	33.19	30	1510	1474	79741374
Haemoglobin increased	153.26	33.19	33	1507	6099	79736749
Serum ferritin increased	78.12	33.19	21	1519	9826	79733022
Transferrin saturation increased	72.26	33.19	10	1530	129	79742719
Diarrhoea	68.68	33.19	84	1456	880405	78862443
Product taste abnormal	61.09	33.19	13	1527	2258	79740590
Peripheral arterial occlusive disease	57.98	33.19	16	1524	8242	79734606
Haematocrit increased	53.66	33.19	13	1527	4021	79738827
Hyperparathyroidism secondary	53.54	33.19	12	1528	2648	79740200
Faeces discoloured	52.11	33.19	20	1520	29107	79713741

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	B03AB02	BLOOD AND BLOOD FORMING ORGANS ANTIANEMIC PREPARATIONS IRON PREPARATIONS Iron trivalent, oral preparations
ATC	V03AE05	VARIOUS ALL OTHER THERAPEUTIC PRODUCTS ALL OTHER THERAPEUTIC PRODUCTS Drugs for treatment of hyperkalemia and hyperphosphatemia
FDA MoA	N0000020074	Phosphate Chelating Activity
FDA EPC	N0000175597	Phosphate Binder

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Hyperphosphatemia	indication	20165001	DOID:0050459

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
EQ 500MG IRON	VELPHORO	VIFOR FRESENIUS	N205109	Nov. 27, 2013	RX	TABLET, CHEWABLE	ORAL	9561251	Jan. 23, 2030	CONTROL OF PHOSPHOROUS LEVELS IN PATIENTS

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
20344-49-4	SECONDARY_CAS_RN
D04616	KEGG_DRUG
4021278	VANDF
4033084	VANDF
C3696416	UMLSCUI
CHEBI:192761	CHEBI
CHEMBL3039566	ChEMBL_ID
DB09146	DRUGBANK_ID
CHEMBL4802224	ChEMBL_ID
CHEMBL1200823	ChEMBL_ID
C000599459	MESH_SUPPLEMENTAL_RECORD_UI
C092844	MESH_SUPPLEMENTAL_RECORD_UI
DB14695	DRUGBANK_ID
1484283	RXNORM
15814	MMSL
221324	MMSL
30331	MMSL
30334	MMSL
d04725	MMSL
d08266	MMSL
007471	NDDF
008975	NDDF
015366	NDDF
1285045009	SNOMEDCT_US
129497004	SNOMEDCT_US
387206004	SNOMEDCT_US
421953007	SNOMEDCT_US
737661000168109	SNOMEDCT_US
9793696	PUBCHEM_CID
87PZU03K0K	UNII

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Velphoro	HUMAN PRESCRIPTION DRUG LABEL	1	49230-645	TABLET, CHEWABLE	500 mg	ORAL	NDA	26 sections
Velphoro	HUMAN PRESCRIPTION DRUG LABEL	1	49230-645	TABLET, CHEWABLE	500 mg	ORAL	NDA	26 sections